These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK, DIRECT Programme Study Group. Lancet; 2008 Oct 18; 372(9647):1394-402. PubMed ID: 18823656 [Abstract] [Full Text] [Related]
3. Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Aldington S, Chaturvedi N. Diabet Med; 2011 Mar 18; 28(3):345-51. PubMed ID: 21309844 [Abstract] [Full Text] [Related]
4. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E, SCAST Study Group. Lancet; 2011 Feb 26; 377(9767):741-50. PubMed ID: 21316752 [Abstract] [Full Text] [Related]
5. The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. Chaturvedi N, Sjoelie AK, Svensson A, DIRECT Programme Study Group. J Renin Angiotensin Aldosterone Syst; 2002 Dec 26; 3(4):255-61. PubMed ID: 12584669 [Abstract] [Full Text] [Related]
6. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH). Palma Gámiz JL, Pêgo M, Contreras EM, Anglada MP, Martínez JO, Esquerra EA, Sagastagoitia Gorostiza JD, Iberian Multicenter Imidapril Study on Hypertension. Clin Ther; 2006 Dec 26; 28(12):2040-51. PubMed ID: 17296460 [Abstract] [Full Text] [Related]
7. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK, DIRECT Study Group. Diabetologia; 2011 Jun 26; 54(6):1298-303. PubMed ID: 21225239 [Abstract] [Full Text] [Related]
8. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Ogihara T, Ueshima K, Nakao K, Fukiyama K, Oba K, Yasuno S, Fujimoto A, Sato T, Matsuoka H, Saruta T, CASE-J Ex Study Group. Hypertens Res; 2011 Dec 26; 34(12):1295-301. PubMed ID: 21833000 [Abstract] [Full Text] [Related]
9. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme. Wright AD, Dodson PM. Eye (Lond); 2010 Jan 26; 24(1):1-6. PubMed ID: 19648902 [Abstract] [Full Text] [Related]
10. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, Wang M, Zhu F, Cheng X, Wei YM, Zhou ZH, Fu M, Liao YH, SOT-AT1 Study Group. Heart; 2011 Mar 26; 97(6):479-84. PubMed ID: 21296780 [Abstract] [Full Text] [Related]
11. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG, FIELD study investigators. Lancet; 2007 Nov 17; 370(9600):1687-97. PubMed ID: 17988728 [Abstract] [Full Text] [Related]
12. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH. Ann Intern Med; 2009 Jul 07; 151(1):11-20, W3-4. PubMed ID: 19451554 [Abstract] [Full Text] [Related]
13. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. Knudsen ST, Andersen NH, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, Poulsen PL, Mogensen CE. Am J Hypertens; 2008 Feb 07; 21(2):172-6. PubMed ID: 18188164 [Abstract] [Full Text] [Related]
14. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N. Clin Ther; 2012 Apr 07; 34(4):838-48. PubMed ID: 22440192 [Abstract] [Full Text] [Related]
17. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study. Tillin T, Orchard T, Malm A, Fuller J, Chaturvedi N. J Hypertens; 2011 Jul 07; 29(7):1457-62. PubMed ID: 21602709 [Abstract] [Full Text] [Related]